compound semaglutide vs compounded tirzepatide trapezoid Ozempic® (semaglutide) and Mounjaro™ (tirzepatide), a major breakthrough for the treatment of obesity 🌟 Wondering about the difference

This webinar with obesity medicine physician Jonathan Bonnet, MD, MPH, a GLP-1RA expert, will answer all your questions about the medications, how they work, their benefits, their side effects, and how they can be combined with lifestyle changes to optimize your weight loss and body composition.

Enjoy a non-invasive, daily dose solution without injections for convenient weight management.

A new ligand against the GPCR GLP-1R acts as a positive allosteric modulator, binding both the receptor and the orthosteric ligand, accessing the peptide ligand within the interface between transmembrane domains 1 and 2 of the receptor.

GLP1-S (20mg) is studied for its potential to influence insulin signaling and appetite regulation in metabolic and endocrine research models.

This makes them cost-efficient, reliable, and a go-to partner for global pharma companies